Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs
Kelly M. Mahar Doan, Joan E. Humphreys, Lindsey O. Webster et al. · Journal of Pharmacology and Experimental Therapeutics · 2002
Cited by 614 works. doi:10.1124/jpet.102.039255
Authors
- Kelly M. Mahar Doan
- Joan E. Humphreys
- Lindsey O. Webster
- Stephen A. Wring
- Larry J. Shampine
- Cosette J. Serabjit‐Singh
- Kimberly K. Adkison
- Joseph W. Polli
References
- Goodman and Gilman's the Pharmacological Basis of Therapeutics
- Drug-like properties and the causes of poor solubility and poor permeability
- GOODMAN and Gilman's the pharmacological basis of therapeutics, 8th ed.
- Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption
- THE CELL BIOLOGY OF THE BLOOD-BRAIN BARRIER
- P-Glycoprotein, a gatekeeper in the blood–brain barrier
- Estimation of Blood-Brain Barrier Crossing of Drugs Using Molecular Size and Shape, and H-Bonding Descriptors
- Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery
- Transporting therapeutics across the blood-brain barrier
- Estimation of Molecular Linear Free Energy Relation Descriptors Using a Group Contribution Approach